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 Plasma levels of bilirubin oxidation products rise in chole-
static liver disease.
 The regio-isomers Z-BOX A and B exhibit distinct pharma-
cokinetics and -dynamics.
 Z-BOX A and B differentially affect the hepatocellular
glutathione redox state.
 Z-BOX A and B differentially modulate the activity of Rev-
erba and Rev-erbb.Raphael A. Seidel, Thierry Claudel,







Degradation of the blood pigment heme
yields the bile pigment bilirubin and the
oxidation products Z-BOX A and Z-BOX B.
Serum concentrations of these bioactive
molecules increase in jaundice and can
impair liver function and integrity.
Amounts of Z-BOX A and Z-BOX B that
are observed during liver failure in
humans have profound effects on hepatic
function when added to cultured liver
cells or infused into healthy rats.
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See Editorial, pages 214–215Background & Aims: Biliverdin and bilirubin were previously cytotoxicity, affected the glutathione redox state, and differen-
considered end products of heme catabolism; now, however, tially modulated activity of Rev-erba and Rev-erbb. Moreover,
there is evidence for further degradation to diverse bioactive
products. Z-BOX A and Z-BOX B arise upon oxidation with
unknown implications for hepatocellular function and integrity.
We studied the impact of Z-BOX A and B on hepatic functions
and explored their alterations in health and cholestatic conditions.
Methods: Functional implications and mechanisms were investi-
gated in rats, hepatocytic HepG2 and HepaRG cells, human
immortalized hepatocytes, and isolated perfused livers. Z-BOX A
and B were determined by liquid chromatography-tandem mass
spectrometry (LC-MS/MS) in acute and acute-on-chronic liver
failure and hereditary unconjugated hyperbilirubinemia.
Results: Z-BOX A and B are found in similar amounts in humans
and rodents under physiological conditions. Serum concentra-
tions increased 20-fold during cholestatic liver failure in
humans (p\0.001) and in hereditary deficiency of bilirubin glu-
curonidation in rats (p\0.001). Pharmacokinetic studies
revealed shorter serum half-life of Z-BOX A compared to its
regio-isomer Z-BOX B (p = 0.035). While both compounds were
taken up by hepatocytes, Z-BOX A was enriched 100-fold and
excreted in bile. Despite their reported vasoconstrictive proper-
ties in the brain vasculature, BOXes did not affect portal hemody-
namics. Both Z-BOX A and B showed dose-dependentJournal of Hepatology 20
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Conclusions: Our data provide evidence that higher-order heme
degradation products, namely Z-BOX A and B, impair hepatocel-
lular integrity and might mediate intra- and extrahepatic
cytotoxic effects previously attributed to hyperbilirubinemia.
Lay summary: Degradation of the blood pigment heme yields the
bile pigment bilirubin and the oxidation products Z-BOX A and
Z-BOX B. Serum concentrations of these bioactive molecules
increase in jaundice and can impair liver function and integrity.
Amounts of Z-BOX A and Z-BOX B that are observed during liver
failure in humans have profound effects on hepatic function
when added to cultured liver cells or infused into healthy rats.
 2017 European Association for the Study of the Liver. Published
by Elsevier B.V. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Heme (iron protoporphyrin IX) serves as a prosthetic group in a
variety of proteins involved in oxygen transport, redox reactions,
and signaling.1 When released extracellularly, labile heme acts as
an alarmin2 and cytotoxic agonist3 that is encountered by scav-
enger systems.4 Intracellular heme concentrations are tightly
controlled by its enzymatic degradation via heme oxygenases
(HO),5 yielding the first-order degradation products biliverdin,
ferrous iron, and carbon monoxide (CO).6,7 The induction of
HO-1 reflects a hallmark of the cellular response to oxidative
stress and confers tissue protection during infection and inflam-
mation.8,9 Bilirubin, generated from biliverdin by biliverdin
reductases, contributes to tissue integrity via its anti-oxidative
properties.10,11 Nevertheless, above a certain threshold bilirubin
is held responsible for intra- and extrahepatic dysfunction,17 vol. 67 j 272–281
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including neurotoxicity and cholemic nephropathy.12,13 In condi-
tions of oxidative stress, unconjugated bilirubin is oxidized to
higher-order degradation products such as the major bilirubin
oxidation end products (BOXes), in particular the regio-isomers
Z-2-(4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)-
acetamide (Z-BOX A) and Z-2-(3-methyl-5-oxo-4-vinyl-
1,5-dihydro-2H-pyrrol-2-ylidene)acetamide (Z-BOX B)14 (Fig. S1).
In subarachnoid hemorrhage, Z-BOX A and B mediate vaso-
constriction, presumably via inhibition of large-conductance
Ca2+- and voltage-dependent Slo1 potassium channels.15,16 How-
ever, systematic assessment of the role of these higher-order
degradation products was hampered so far by a lack of analytical
tools and BOXes of appropriate purity.16–18 To enable the system-
atic assessment of biological fate and function, we recently
established syntheses,19,20 purification, and sensitive analytics
of Z-BOX A and B.21 Given the central role of the liver in heme
degradation, we studied pharmacokinetics and -dynamics of
Z-BOX A and B and explored their impact on hepatic function.
Materials and methods
Preparation of BOXes
Z-BOX A and Z-BOX B were prepared via in vitro bilirubin oxidation and chemical
synthesis as described.19,20 Isomer purity was confirmed by liquid chromatogra-
phy, coupled to tandem mass spectrometry (LC-MS/MS) and nuclear magnetic
resonance spectroscopy. Water solubility and partition constants (1-octanol/
water) were determined spectrophotometrically.
Quantification of BOXes
Simultaneous determination of Z-BOX A and B was achieved via LC-MS/MS.21 To
assess possible differences between Z-BOXes concentrations in serum and plasma
preparations human serum and plasma samples were spiked with 80 or
300 nmolL1 of both analytes and analyzed accordingly. Gallstones were extracted
using acetonitrile/isopropanol/water (2/1/1, v/v/v; 10 llmg1 concrement).
Human specimen collection
All biomaterials were collected after approval by the ethics committee of Jena
University and with informed consent from all subjects or their legal representa-
tives (3548-08/12; 2435-12/08; 3624-11/12; 2712-12/09; 2160-11/07; 4406-
04/15). Plasma samples of 28 patients were obtained upon fulfilling diagnostic
criteria for liver failure (acute, ALF, n = 9; acute-on-chronic, ACLF, n = 15; trans-
plant failure, n = 4). Ten healthy volunteers served as controls.
Rodents
Male Wistar rats (286–539 g, Harlan Laboratories), homozygous Gunn rats (165–
333 g, in-house breeding22), and C57BL/6J mice (25–30 g, in-house breeding)
were used with the approval of the institutional animal welfare committees
(Thuringian State Office for Consumer Protection and Food Safety, Bad Langen-
salza, Germany, 02-001/11, 02-058/14; Animal Ethics Committee of the Univer-
sity of Groningen, Groningen, The Netherlands, DEC6660A) under isoflurane
anesthesia.
PK/PD studies
Rats were catheterized via the right jugular vein to inject Z-BOX A and Z-BOX B
(26.7 lg(kg body weight)1 in PBS containing 0.25% dimethyl sulfoxide, DMSO),
the left carotid artery for blood sampling, and bile duct for bile collection. Urine
was sampled before and 60 min after application.
Portal hemodynamics
Rat livers were perfused via the portal vein with carbogen-saturated Krebs
Henseleit buffer (Biochrom, Berlin, Germany) containing 2 gL1 glucose, usingJournal of Hepatology 201a body weight-adapted constant flow rate of 100 ml(kg body weightmin)1.
Z-BOX A, Z-BOX B, or vehicle was individually administered to the main flow.
In parallel to bile sampling, portal pressure was measured (TSD104A, 10 or 20
Hz, Biopac Systems, Goleta, CA, USA) and 0.01 Hz low-pass filtered (OriginLab,
Northampton, USA).
Cell culture
All reagents were obtained from Life Technologies (Darmstadt, Germany), unless
otherwise stated. HepG2 cells (DSMZ, Braunschweig, Germany; authenticated by
short tandem repeats (STR) profiling) were cultured in the dark at 37C using
Dulbecco’s Modified Eagle’s Medium (DMEM)/Nutrient Mixture F-12 (1:1), sup-
plemented with 10% fetal bovine serum (FBS), 1 lgml1 streptomycin, and
1 Uml1 penicillin. Measurements of metabolic rate (MTT assay) and lactate
dehydrogenase (LDH) release (Roche Diagnostics, Mannheim, Germany) were con-
ducted according to themanufacturer’s instructions, in medium containing 1% FBS
after 96 h treatment with Z-BOX A, Z-BOX B, or vehicle control. EC50
values were calculated using the model f = min + (maxmin)/(1 + 10log EC50  x).
Changes in the intracellular glutathione redox potential were measured with a
genetically encoded fluorescent sensor, consisting of a fusion of redox-sensitive
green fluorescent protein (roGFP2) and glutaredoxin 1 (Grx1).23 Ratiometric fluo-
rescence measurements (400/470 nm; photodiode and Polychrome V monochro-
mator, TILL Photonics, Munich, Germany) of individual HepG2 cells were
performed after 1 h incubation with BOXes in culturing medium. HepaRG
(INSERM Transfert, Paris, France) cells were cultured using Williams’ E medium
supplemented with 10% FBS, 2 mmol  L1 glutamine, 2.5 ng  ml1 insulin,
24.7 lg  ml1 hydrocortisone 21-hemisuccinate, 1 lg  ml1 streptomycin, and
1 U  ml1 penicillin. Terminal differentiation was induced by supplementing 2%
DMSO for two weeks. Morphology of HepG2 and HepaRG cells was studied
after incubation with supraphysiological concentrations (500 lmolL1 or
700 lmolL1) of Z-BOXes after 24 h and 48 h. Media containing Z-BOX A,
Z-BOX B, and vehicle were prepared with 0.25% (HepG2) or 1.0% (HepaRG) DMSO.
Human immortalized hepatocytes (HIH) were already described,24 a subclone was
obtained after serial passages and grown in DMEM with 10% FBS and 0.5% peni-
cillin/streptomycin (ThermoFisher, Austria) and incubated for 48 h, with or with-
out Z-BOX A or Z-BOX B at 15 lmolL1 or SR8278 (Tocris, Biomedica, Austria).
Quantitative real-time PCR (qPCR)
After RNA extraction (Trireagent) and retro-transcription (MMLV, Sigma, Austria),
qPCR was performed using the SYBRgreen method (SYBR Select Master Mix;
ABIprism 7500, ThermoFisher, Austria). Primer sequences are provided in
Table S1.
Electrophoretic mobility shift assays
Double-stranded oligonucleotides were end-labeled with [c32P]ATP using T4-
polynucleotide kinase. Nuclear or cytosolic protein extracts (2 lg; Supplemen-
tary material) were incubated for 15 min at room temperature in 20 ll binding
buffer (30 mmolL1 HEPES, pH 7.5; 60 mmolL1 KCl; 0.5% glycerol; 0.1%
Triton X100; 1 mmolL1 DTT), before the radiolabeled probe (0.5 ng) was
added. Binding reactions were further incubated for 15 min with Rev-erba
(sc-135241) or Rev-erbb antibodies (sc-47621, Santa-Cruz, Heidelberg,
Germany) and resolved by 6% or 4% polyacrylamide gel electrophoresis in
0.25X Tris-Borate-EDTA buffer. Oligonucleotides are provided in the Supple-
mentary material.
Fluorescence microscopy
Cells were fixed in 4% formaldehyde prior to staining with 40 ,6-diamidino-
2-phenylindole (DAPI) and AlexaFluor 488 labeled phalloidin and studied on a
LSM-780 laser scanning microscope (Zeiss, Jena, Germany).
Electron microscopy
Scanning electron microscopy was performed on LEO-1530 and LEO-1450VP
instruments (Zeiss, Oberkochen, Germany). Cells were grown on glass cover slips
and fixed with 2.5% glutaraldehyde in 0.1 M cacodylate buffer. Samples were
dehydrated in ascending ethanol concentrations, critical-point dried, and sputter
coated with gold. Statistical image evaluation was conducted in 182  124 lm

































Statistical analysis was carried out using SigmaPlot (Systat, Erkrath, Germany).
Data (mean ± SEM) were analyzed by t test, one-way ANOVA using Holm-Sidak
post hoc analysis, or the corresponding non-parametric tests if criteria were vio-
lated. Correlation analysis was assessed with Pearson’s product moment. p values
below 0.05 were considered significant.
For further details regarding the materials and methods used, please refer to
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Fig. 1. Z-BOX A and Z-BOX B in health and cholestatic disease across species.
(A) Mean concentrations of Z-BOX A + B in plasma of patients with liver failure
(n = 28) compared to healthy controls (n = 10). ACLF, acute-on-chronic liver
failure; ALF, acute liver failure. (B) Z-BOX A + B and bilirubin concentrations in the
corresponding samples of human liver failure (filled symbols) compared to
healthy controls (empty symbols). (C) Mean concentrations of Z-BOX A + B in
serum/plasma samples of hyperbilirubinemic Gunn rats (animal model of Crigler-
Najjar syndrome type I, n = 14) compared to non-hyperbilirubinemic Wistar rats
(n = 12). (D) Z-BOX A + B and bilirubin concentrations in the corresponding
samples of Gunn rats (filled symbols) compared to Wistar rats as control (empty
symbols). (E) Cross-species comparison of the mean ratios between Z-BOX A + B
and total bilirubin concentrations in human and rat samples. (F) Correlation
between the Z-BOX A and B concentrations in all 38 human and 26 rat samples.
Statistics: t test; ***p\0.001; Pearson’s r was calculated for the data in B, D, F.Results
BOXes occur under physiological conditions and increase in
cholestasis
Concentrations of Z-BOX A and B in the systemic circulation have
not been investigated yet. Therefore, we first determined serum/
plasma concentrations of Z-BOX A and B in health, liver failure,
and bilirubin conjugation failure (Fig. 1). The mean total serum
concentration of Z-BOX A and B in healthy humans was
25.4 ± 3.4 nmolL1 (n = 10). We observed significantly higher
concentrations of Z-BOX A and B (504.3 ± 30.3 nmolL1,
p\0.001; n = 28) in patients with liver failure, which is associ-
ated with impaired hepatobiliary excretion (Fig. 1A, B). The mean
total Z-BOX A and B concentrations in female
(461.8 ± 54.7 nmolL1; n = 11) were similar compared to those
in male patients (531.8 ± 34.9 nmolL1, p\0.26, n = 17). Regard-
ing the subgroup of alcoholic liver disease (418.5 ± 44.8 nmolL1,
n = 9) lower values compared to the other etiologies
(544.9 ± 36.3 nmolL1, p = 0.049; n = 19) were observed. Total
concentrations of Z-BOX A and B in healthy Wistar rats
(19.1 ± 4.6 nmolL1; n = 12) and C57BL/6J mice
(14.4 ± 0.8 nmolL1; n = 5) did not differ from serum concentra-
tions in healthy humans (p[0.85). In contrast, the serum of Gunn
rats with congenital hyperbilirubinemia exhibited significantly
higher BOXes concentrations (136.9 ± 15.1 nmolL1, p\0.001;
n = 14) compared to non-hyperbilirubinemic Wistar rats
(Fig. 1C, D). In all samples, Z-BOX A and B concentrations strongly
correlated with each other (r[0.99; p = 11055; Fig. 1F) and with
the concentrations of unconjugated and total bilirubin (r[0.86;
p = 41019; Fig. 1B, D; Fig. S2). Values of BOXes obtained in
spiked corresponding serum and plasma samples did not differ
from each other (concentrations in serum compared to those in
plasma: Z-BOX A, 105.0 ± 3.1%, p = 0.18; Z-BOX B, 104.6 ± 2.3%,
p = 0.10; n = 14 pairs; paired t test).
Yield of the regio-isomers in vitro
To better interpret blood concentrations of both regio-isomers in
the light of PK/PD data we assessed their relative yield upon
in vitro degradation of bilirubin with hydrogen peroxide, which
led to formation of 1.5% Z-BOX A and 0.8% Z-BOX B, respectively.
The regio-isomers Z-BOX A and B have different pharmacokinetics
We then investigated whether the two regio-isomers Z-BOX A
and B exhibit distinct pharmacokinetics. After i.v. bolus injection
of equimolar Z-BOX A and B into rats, the peak serum concentra-
tions of both compounds were reached at 3.5 min (Fig. 2A, B).
The serum disappearances exhibited clearly distinguishable dis-
tribution (a) and elimination (b) phases (inserts in Fig. 2A, B;274 Journal of Hepatology 201Table. S2). Applying a two-compartment model, both compounds
were dispersed in similar relative distribution volumes of
1.0 Lkg1 within the a phase (15 min), tantamount to a uni-
form spread into the whole-body volume. Elimination parame-
ters from first-order kinetics revealed a significantly lower
serum half-live of Z-BOX A (31.0 ± 5.5 min) compared to Z-BOX
B (55.4 ± 7.9 min, p = 0.035; n = 5; Fig. 2C). To foster interpreta-
tion of PK/PD, we determined water solubility (103.6 mgL1
and 76.4 mgL1) and partition constants (log POW = 0.92 and
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Fig. 2. Pharmacokinetics of Z-BOX A and Z-BOX B in rats. (A, B) Serum concentrations of Z-BOX A (A) and Z-BOX B (B) as a function of time after i.v. bolus injection of
equimolar Z-BOX A and B (26.7 lg(kg body weight)1) in Wistar rats at t = 0; insets illustrate distribution (empty symbols) and elimination (filled symbols) phases. (C)
Mean serum elimination half-lives of Z-BOX A and B. (D, E) Biliary excretion profiles of Z-BOX A (D) and Z-BOX B (E) of the same experiments. Inset in E shows biliary Z-BOX
B after administration of this isomer. (F) Mean absolute amounts of Z-BOX A and B excreted into bile. (G, H) Biliary excretion profiles of Z-BOX A (G) and Z-BOX B (H) upon
individual perfusion of rat livers with 10 lmolL1 Z-BOX A (G) and Z-BOX B (H) for 10 min. Application of BOXes is indicated by the bars. Insets in G and H show bile flow as
a function of time with the application of Z-BOX A and Z-BOX B, respectively. (I) Mean absolute amounts of Z-BOX A and B excreted into bile upon liver perfusion. Data
points are mean ± SEM (A-F, n = 5; G-I, n = 3). Statistics: t test (C), Mann-Whitney U test (F, I), repeated measures ANOVA (insets in G, H); *p\0.05; **p\0.01.
JOURNAL OF HEPATOLOGYBOXes are actively excreted into bile
Since Z-BOX A and B were cleared from the circulation after bolus
injection, we asked whether biliary and urinary elimination
occurred. We detected both compounds in the bile before and
after i.v. bolus injection into rats. Notably, we found only trace
amounts of these BOXes in corresponding urine samples of the
same rats before (Z-BOX A + B, 8.4 ± 8.4 nmolL1, n = 8) and
60 min after bolus injection (Z-BOX A + B, 14.7 ± 9.5 nmolL1,
p[0.64; n = 8). Excretion of Z-BOX A and B into bile, however,
was markedly different between the regio-isomers (Fig. 2D–F):
Z-BOX A and B concentrations in bile before i.v. bolus
(72.1 ± 8.4 nmolL1; 320.2 ± 66.0 nmolL1; n = 8) were signifi-
cantly higher than the corresponding serum concentrations
(4.8 ± 2.8 nmolL1, p\0.001; 12.0 ± 5.6 nmolL1, p\0.001;
n = 8). Z-BOX A was enriched [30-fold and eliminated in bile
with a mean peak concentration of 7.63 ± 1.64 lmolL1 (n = 5),
measured 8.5 min after peak serum concentration (Fig. 2A, D).
In contrast, Z-BOX B exhibited a different excretion profile and
appeared at significantly lower peak concentrations in bile
(371.7 ± 89.5 nmolL1, measured 1.0 min after substance appli-
cation; p = 0.0022, compared to Z-BOX A in bile; n = 5;
Fig. 2D, E). To test whether the different excretion kinetics of
Z-BOX A and B are due to competition between the regio-
isomers, we solely injected Z-BOX B into rats in separate
experiments (n = 3). In such experiments, bile concentrations
of Z-BOX B were significantly increased (areas under the curves:
44.9 ± 18.9 lmolL1min vs. 8.72 ± 3.39 lmolL1min, p = 0.047;
n = 3 and 5), albeit the excretion profiles were not different from
those obtained after equimolar application of both regio-isomers
(Fig. 2E, inset). Once the peak concentration of Z-BOX A was
reached after i.v. bolus, the Z-BOX A concentrations in bile were
consistently [30 times higher than in serum. Within 50 min
after injection of both regio-isomers, the overall amounts of
non-metabolized compounds excreted into bile (Fig. 2F) were
42.9% (Z-BOX A) and 2.4% (Z-BOX B) of these BOXes in wholeJournal of Hepatology 201blood, reflecting 3.88% Z-BOX A and 0.18% Z-BOX B, respectively,
of the administered molar amounts. In addition to the PK studies
after single i.v. bolus, we determined the individual biliary excre-
tion profiles upon 10-minute applications of Z-BOX A and B in
isolated perfused rat livers (Fig. 2G–I). Perfusions with
10 lmolL1 BOXes resulted in the excretion of [100-fold
enriched Z-BOX A (1.04 ± 0.17 mmolL1, n = 3), whereas Z-BOX
B (11.4 ± 2.3 lmolL1, p = 0.58; n = 3) was not excreted actively
into the bile.
Z-BOX A and B in human bile and gallstones
To confirm biliary excretion of Z-BOX A and B in humans without
access to bile from healthy individuals, we determined Z-BOX A
and B in bile samples obtained upon cholecystectomy. Z-BOX A
(68.9–860 nmolL1) and Z-BOX B (48.8–789 nmolL1) were
found in bile as well as in corresponding gallstones (Table S3,
Fig. S3).
Z-BOX A and B do not alter portal hemodynamics
As Z-BOX A and B induce vasoconstriction of cerebral vessels15
and as heme increases portal resistance (Schleser et al., manu-
script submitted) we hypothesized that Z-BOX A and B may alter
portal hemodynamics. Isolated rat livers were perfused with
Z-BOX A or B (Fig. 3A, B). Notably, the portal pressure did not
change during the administrations or in the wash-out periods
(Z-BOX A, p = 0.38; Z-BOX B, p[0.12; referencing to baseline;
n = 3).
Z-BOX A and B impair hepatocellular metabolism
We then asked whether Z-BOX A and B may affect hepatocellular
integrity and metabolism. HepG2 cells responded to Z-BOX A and
B with a dose-dependent increase of LDH release without signif-
icant differences between the regio-isomers (Z-BOX A,7 vol. 67 j 272–281 275
Time (min)





































































Fig. 3. Portal hemodynamics upon administration of Z-BOX A and Z-BOX B in
rats. Isolated perfused livers were equilibrated for[10 min prior to treatment. (A,
B) Changes in portal pressure upon perfusion with 10 lmolL1 Z-BOX A (A) and
Z-BOX B (B). Application of BOXes is indicated by the bars. Insets in A, B display
representative profiles of the raw (grey) and low-pass filtered (black) portal
pressure. Data points are mean ± SEM (n = 3); Statistics: repeated measures
ANOVA.
Research ArticleEC50 = 302 ± 125 lmolL1; Z-BOX B, 179 ± 94 lmolL1; n = 5).
Of note, absolute cytotoxicity was marginal (Fig. 4A–C). The
MTT assay revealed a dose-dependent impairment of metabolic
rates with IC50 = 723 ± 283 lmolL1 (Z-BOX A; n = 3) and
509 ± 247 lmolL1 (Z-BOX B; n = 3), respectively (Fig. 4D–F).
Z-BOX A selectively affects hepatocellular cytoskeletal organization
As BOXes are significantly enriched in bile, the canalicular
membranes of hepatocytes are subjected to much higher Z-BOX
A and B concentrations compared to BOXes concentrations in
blood. HepG2 cells reacted differently upon exposure to theA
Z-BOX B (mol·L-1)







































































Fig. 4. Cytotoxicity and metabolic rate after incubation with Z-BOX A and B in HepG2
upon treatment with Z-BOX A (A) and Z-BOX B (B) for 96 h; superimposed sigmoid fits. (
dependent metabolic rate as measured by MTT assay upon treatment with Z-BOX A (C
inhibitory concentrations of metabolic rate (n = 3). Light blue areas in A, B and D, E illustr
t test.
276 Journal of Hepatology 201regio-isomers Z-BOX A and B. While treatment with
125 lmolL1 Z-BOX A induced a morphological transformation
from brick-like to spherically shaped cell morphology (Fig. 5)
within few hours, the morphology of Z-BOX B-treated cells did
not differ from control cells (Fig. 5A, B). Cells treated with
Z-BOX A for 24 h were classified into three distinct groups: (I)
Spherical cells with a strongly interfolded cell membrane and
surface extensions distributed around the whole cell body associ-
ated with diminished cell-cell and cell surface contacts. (II) Cells
of intermediate morphology with features of I and III. (III) Flatly
attached cells with brick-like morphology (as the vehicle control)
with brush border-like villi at the apical pole and numerous cell-
cell contacts. In contrast, cells treated with Z-BOX B did not differ
from the control (p[0.16; n = 543 and 744 individual cells/treat-
ment; Fig. 5C). Notably, after Z-BOX A treatment for 48 h, the
fraction of spherical cells did not change compared to 24-h incu-
bation with Z-BOX A (p[0.14; n = 193 and 412 individual cells/
treatment). However, after 48 h, three noticeable sub-types of
the type I cells were distinguishable (Fig. S4): (a) cells with intact
villi, (b) cells showing extensive blebbing of the cell membrane,
and (c) cells without any visible cell surface extensions.
Morphological alterations are specific to hepatocytes
To confirm the Z-BOX A-specific effect in a second in vitro model,
we investigated the bi-potent progenitor cell line HepaRG before
and after terminal differentiation into its hepatocyte-like and
biliary-like phenotypes. While undifferentiated HepaRG cells
responded uniformly to Z-BOX A like HepG2, terminally differen-
tiated HepaRG cells responded heterogeneously, depending on
the particular phenotype. The morphology of the biliary-like
phenotype, which served as an endogenous control, remainedD
Z-BOX A (mol·L-1)







































































cells. (A, B) Dose-dependent LDH release as a surrogate of hepatocellular damage
C) Mean half maximal effective concentrations of LDH release (n = 5) (D, E) Dose-
) and Z-BOX B (D) for 96 h; superimposed sigmoid fits. (F) Mean half maximal
ate 10% change of the effect compared to control. Data are mean ± SEM. Statistics:
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Cell morphology (24 h)
Fig. 5. The regio-isomer Z-BOX A alters specifically hepatocellular morphology. (A) Representative fluorescence micrographs of HepG2 cells after incubation with high-
dose Z-BOX A, Z-BOX B, or control for 24 h. (B) Representative scanning electron micrographs of HepG2 cells after treatment with high-dose Z-BOX A, Z-BOX B, or control for
24 h. (C) Statistical evaluation of the different morphotypes (Brick-like, Intermediate, Spherical) after 24 h. (D) Representative scanning electron micrographs of terminally
differentiated HepaRG cells after treatment with high-dose Z-BOX A or control for 24 h. The hepatocyte-like phenotype and the biliary-like phenotype (endogenous control)
are growing in juxtaposition. Data are mean ± SEM (n = 502 to 744 cells/treatment); Statistics: one-way ANOVA; ***p\0.001.
JOURNAL OF HEPATOLOGYunaffected. The hepatocyte-like phenotype exhibited an altered
morphology with a loss of cell-cell contacts and membrane bleb-
bing (Fig. 5D).BOXes interfere with the cytoplasmic glutathione redox potential
As the structures of Z-BOX A and B suggest reactivity towards
thiol groups, we explored whether these BOXes affect the hepato-
cellular glutathione redox state. Using the genetically encoded
fluorescent redox sensor Grx1-roGFP2,23 we demonstrated that
Z-BOX A and B significantly shift the glutathione redox potential
to a more oxidized state (as measured via the formation of disul-
fide bonds in the fluorescent sensor) (Fig. 6A, Fig. S5). Applying LC
and high-resolution MS, we further documented the formation of
glutathione mono-adducts of both Z-BOX A and B in vitro (Fig. 6B,
Fig. S6). The analyses revealed several successively eluting com-
pounds with the same high-resolution mass. Tentative chemical
structures and UV absorbance spectra of these adducts, which
are similar to those of untransformed Z-BOX A and B,19,20 are
depicted in Figs. S6 and S7. Notably, Z-BOX A showed 10-fold
higher reactivity towards glutathione than Z-BOX B (Fig. 6B).
We also investigated whether Z-BOX A and B may increase lipid
peroxidation in HepG2 cells (experimental details see Supple-
mentary material). Direct incubations with these BOXes for 2 h
did not result in significant changes of lipid peroxidation. After
24-h priming with Z-BOX A, the cells were (along with their
changed morphology) less susceptible to oxidative stress,
induced by tert-butylhydroperoxide (Fig. S8).Journal of Hepatology 201Z-BOX A and B modify gene expression by modulating the nuclear
receptors Rev-erba and Rev-erbb
We hypothesized that, as demonstrated for heme, also the Z-BOX
A or B regio-isomers may interact with members of the Rev-erb
family of nuclear receptors. After exposure to either Z-BOX A or
B, HIH showed a repression of the Rev-erba and b target gene
PEPCK (p\0.001; n = 3; Fig. 6C).25,26 Surprisingly, Z-BOX A and
B differentially regulated mRNA expression of Rev-erbs itself:
Z-BOX A repressed Rev-erba (p\0.001; n = 3) without affecting
Rev-erbb expression, while Z-BOX B had no impact on Rev-erba
or b gene expression. Furthermore, gene expression of several
other targets of Rev-erbs (lipid metabolism genes fatty acid
desaturase 2 [FADS2]; 3-hydroxy-3-methylglutaryl-CoA reduc-
tase [HMGCR]; the limiting step in bile acid synthesis cytochrome
P450 isoenzyme 7A1 [CYP7A1]) was explored (Fig. 6C).27 FADS2
and HMGCR RNA expression were increased by Z-BOX B
(p\0.001; n = 3), while Z-BOX A did not affect their expression;
however, both BOXes repressed CYP7A1 (p\0.001; n = 3). We
also performed electrophoretic mobility shift assays using
revDR2 and its mutant variant abolishing Rev-erbs binding and
cytosolic or nuclear extracts of HIH (Fig. 6D). Nuclear extracts
of control cells weakly bound to the revDR2, while Z-BOX A
nuclear extracts showed a strong binding, which was lost with
revDR2 mutant. Z-BOX B nuclear extracts revealed two potential
complexes of high and low size. Incubation with the revDR2
mutant identified the lower size complex as specific. Moreover,
binding specificity was underlined by super-shift assays using
antibodies against Rev-erba or b and compared with the7 vol. 67 j 272–281 277
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Fig. 6. Z-BOX A and B alter hepatocellular redox potential, differentially react with glutathione, and differentially modulate the activities of Rev-erba and b. (A)
Fluorescence ratio of the redox sensor Grx1-roGFP2 in HepG2 cells as a reporter of the intracellular glutathione redox potential; transfected HepG2 cells were incubated
with each treatment at 37C for 1 h prior to measuring the fluorescence ratio at room temperature. (B) Extracted ion current chromatograms with a mass tolerance of 2 ppm
of Z-BOX A and B (m/z = 179.0815, dashed lines) and their stable mono-adducts with glutathione (m/z = 486.1653, solid lines) from LC-high-resolution-MS analysis after
non-enzymatic incubation for 5 d. Multiple glutathione-BOXes adduct (GS-Z-BOX A/B) peaks indicate different diastereomers (magnification in inset, experimental details
and further data see Supplementary material). (C) mRNA expression of Rev-erba, Rev-erbb, phosphoenolpyruvate carboxykinase (PEPCK), fatty acid desaturase 2 (FADS2), 3-
hydroxy-3-methylglutaryl-CoA reductase (HMGCR), and CYP7A1 in human immortalized hepatocytes (HIH) after stimulation with 15 lmolL1 Z-BOX A or B (n = 3 each) for
48 h (control cells set to 100). (D) Electrophoretic mobility shift assay of nuclear (n) or cytosolic (c) protein extracts (2 lg) of HIH upon treatment with or without
15 lmolL1 Z-BOX A or Z-BOX B using revDR2 and its mutant to repress binding of Rev-erbs. Arrows indicate binding of Z-BOX A (light blue) or Z-BOX B (dark blue).
(E) Electrophoretic mobility super-shift assay using antibodies against Rev-erba (Aba) or Rev-erbb (Abb) and the Rev-erba modulator SR8278 and cytosolic (c) or nuclear
(n) extracts of HIH treated with or without 15 lmolL1 of Z-BOX A or B. Arrows indicate reduced binding after pre-incubation with Rev-erba (black) and Rev-erbb (grey)
antibodies. Data in A and C are mean ± SEM (A: n = 46 to 82; C; n = 3). Statistics: One-way ANOVA; ***p\0.001.
Research ArticleRev-erba modulator SR8278 (Fig. 6E). Nuclear extracts of cells
incubated with SR8278 showed a complex bound to revDR2, at
the same molecular size as the Z-BOX A complex. Z-BOX A
nuclear extract bound to revDR2, while pre-incubation of the
nuclear extract with Rev-erba antibody reduced binding – thus
demonstrating that Rev-erba was part of the complex and that
its binding increased after Z-BOX A treatment. Similarly, Z-BOX
B nuclear extract bound to the revDR2 oligos, while pre-
incubation of the Z-BOX B extracts with a Rev-erbb antibody
abolished binding. Taken together, our results suggest that
Z-BOX A acts as a modulator of Rev-erba activity by increasing
its binding to specific DNA response elements and repressing
its own expression, while Z-BOX B increased the binding of
Rev-erbb and modulated gene expression of FADS2 and HMGCR.Discussion
The liver plays a key-role in heme catabolism, yielding equimolar
amounts of biliverdin, ferrous iron, and carbon monoxide  each
known to affect hepatic function or integrity.28,29 However, there
is a lack of data on formation, fate, and function of higher-order
heme degradation products, in particular, of the regio-isomers
Z-BOX A and Z-BOX B. Here, we characterize formation, kinetics,
and impact of Z-BOX A and B on hepatic function and integrity.278 Journal of Hepatology 201We demonstrate similar basal concentrations of Z-BOX A and B
in healthy humans, rats, and mice. Substantially higher concen-
trations were found in patients with liver failure and in the Gunn
rat model of congenital hyperbilirubinemia. Hepatocytes differ-
ently interacted with the regio-isomers Z-BOX A and B, leading
to significantly different serum half-lives and biliary excretion
profiles. While both acted as partial agonists of Rev-erbs and
showed similar cytotoxicity, only Z-BOX A, which was strongly
enriched in bile, triggered a characteristic remodeling of the hep-
atocellular cytoskeleton. Consistent with the altered cytoskeletal
morphology and the effects on the central transcriptional regula-
tors Rev-erba and b that would suggest sustained impairment of
excretory function, acute effects on bile production were
observed in vivo (data not shown), but not in the isolated per-
fused liver preparation (Fig. 2G, H), in which the concentration
of BOXes and bile salts remain constant. In contrast to single
bolus injections, continued presence of endogenous Z-BOX A
and B in patients and the substantial enrichment primarily of
Z-BOX A may anticipate even stronger BOXes-triggered hepato-
cellular and extrahepatic effects under cholestatic conditions.
As such, the molecular identification of Rev-erba and b as targets
of Z-BOX A and B is in line with their distinct pharmacokinetics.
Rev-erbs are nuclear receptors coordinating lipid, glucose and
bile acid synthesis, as well as phase I and II detoxification
enzymes.27 In addition, Rev-erbs are part of the circadian clock7 vol. 67 j 272–281
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system,30 which is required to coordinate endo- and xenobiotic
metabolism,31 as evident in Rev-erba/b double knock-out
mice.32,33 Intriguingly, Rev-erbs activation by Z-BOX A and B
did not display the classical gene expression signature, leading
to the hypothesis that Z-BOX A and B affected Rev-erbs differ-
ently. This might be due to the presence of endogenous ligands
(heme and CO34) that are prevented from fully activating Rev-
erbs by Z-BOX A and B through competition for the ligand binding
domain access, or by modification of the oxidative stress, leading
to changes in key cysteine residues of the ligand binding
domain.35 Repression of CYP7A1 as rate-limiting enzyme of bile
acid synthesis by both BOXes may be considered a potentially
protective mechanism against cholestasis with associated bile
acid toxicity. Furthermore, the molecular reactivity of Z-BOX A
and B towards thiol groups was shown with respect to glu-
tathione, which constitutes the major hepatocellular redox sys-
tem. As Z-BOX A and B altered the glutathione redox state
different from direct oxidants, e.g. hydrogen peroxide at the same
concentration, we hypothesize that Z-BOX A and B differently
interfere with the glutathione system. Z-BOX A and B did neither
increase lipid peroxidation after direct application nor led to a
sensitization towards oxidative stress in vitro. We thus conclude
that the formation of higher-order heme degradation products
contributes to the detoxification of reactive oxygen species
(ROS), despite their interaction with GSH.
Based on the cerebrovascular effects of BOXes,14,15 we
hypothesized that they might induce vasoconstriction in the por-
tal circulation, which was however not the case. Although an in-
depth interpretation of these divergent results in both vascular
beds is beyond the scope of the present study, we propose that
the nature of the effector cells, i.e. smooth muscle cells for the
cerebrovascular effects and presumably hepatic stellate cells for
the portal hemodynamics, might explain this discrepancy.
Although BOXes might affect terminal portal venules, available
evidence would point towards a primary action of heme36 and
first-order degradation products, in particular CO,37 act primarily
on hepatic stellate cells with a distinctly different contractile
apparatus compared to smooth muscle cells.
Hepatocytes reacted differently towards the regio-isomers
Z-BOX A and B. The specificity for regio-isomers is distinctly
demonstrated by the differential binding to Rev-erba and b,
respectively. Furthermore, the pharmacokinetic characteristics
of Z-BOX A and B showed significant differences in serum disap-
pearance rates and biliary excretion.
The mechanism of bilirubin degradation through ROS-
mediated conversions has not been elucidated yet. Based on the
different chemical yields of the regio-isomers after in vitro degra-
dation of bilirubin, we assume that Z-BOX A is also formed in a
twofold excess in vivo. The approximately twofold shorter serum
half-live of Z-BOX A compared to Z-BOX B is expected to compen-
sate these unequal production rates leading to similar equilib-
rium concentrations of both regio-isomers in the bloodstream
as observed in the present study (Fig. 1). We demonstrated in rats
that elimination into the bile substantially contributes to the
serum clearance, in particular of Z-BOX A. Although the baseline
concentrations of Z-BOX B in bile were approximately four times
higher than those of Z-BOX A, primarily Z-BOX A was excreted
and strongly enriched in the bile after i.v. bolus administration.
The fact that Z-BOX B concentrations were significantly higherJournal of Hepatology 201if solely Z-BOX B was administered strongly indicates a competi-
tion between both regio-isomers. Although the mechanistic back-
ground for the preference of Z-BOX A remains to be elucidated,
we conclude that the presence of Z-BOX A suppresses the excre-
tion of its isomer, Z-BOX B. The serum disappearance of Z-BOX B
without marked excretion of the unchanged molecule into bile
strongly suggests further metabolic conversions prior to its elim-
ination. The immediate and selective enrichment of Z-BOX A in
bile illustrates the availability of suitable transport mechanisms
to lower serum concentrations. It further supports the notion that
higher concentrations, as required for the rearrangement of the
canalicular cell pole, can be achieved locally in vivo. Human bile
samples from patients subjected to cholecystectomy exhibited
moderately higher concentrations of Z-BOX A compared to
Z-BOX B, which is in contrast to the baseline concentrations of
these compounds in the bile of rats. Beyond an altered composi-
tion of the pathologic bile samples, this discrepancy may be due
to potential formation of these BOXes from heme-derived tetra-
pyrroles, intermediate bilirubin oxidation products, or intestinal
microbiota.
To support hepatocellular excretion into bile, microvilli pro-
vide a surface enhancement on the canalicular pole to facilitate
transporter insertion and substance delivery.38 Upon Z-BOX A
treatment, HepG2 cells reacted with the reorganization of their
actin cytoskeleton, leading to formation of spherical cell bodies
and loss of polarity. It is noteworthy that these effects were
observed in the HepG2 cell line at substantially higher concentra-
tions than those measured in patient plasma. However, the sub-
stantial (100-fold) enrichment of Z-BOX A across the
hepatocellular route of excretion as well as the very long expo-
sure intervals under conditions of cholestasis support the poten-
tial biological significance of alterations in brush border
morphology. This effect was confirmed in a second cell line, i.e.
terminally differentiated HepaRG cells, where the biliary-like
phenotype represented an endogenous control.39 The diverging
reactivity of these two phenotypes towards Z-BOX A treatment
is consistent with the presence of specific up-take systems for
Z-BOX A that seem to be restricted to the hepatocyte-like pheno-
type. Hepatocellular stress induced by BOXes may impair bile
secretory function. Interestingly, such cholestatic effects of BOXes
may resemble cholestatic liver and bile duct injury induced by
precursors of heme, in particular, protoporpyrins accumulating
due to hereditary absence or chemical inhibition of ferrochelatase
activity in humans with or mouse models of erythropoietic
protoporphyria.40
In summary, we demonstrate that Z-BOX A and B are bioactive
endogenous degradation products of heme that differently inter-
act with the liver. Consequently, our data introduce the concept
that cytotoxic effects so far solely attributed to bilirubin might,
at least in part, be mediated by higher-order degradation prod-
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